http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Patients with Moderate-To-Severe Pruritus
-
Cara Therapeutics (CARA) Announces Oral KORSUVA Data Selected for Late-Breaking Presentation at AAD
-
Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 American Academy of Dermatology Annual Meeting
-
Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 American Academy of Dermatology Annual Meeting
-
Cara Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
-
Cara Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
-
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients
-
Cara Therapeutics (CARA) announces Kapruvia receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients
-
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients
-
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients
-
Cara Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
-
Cara Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
-
Cara Therapeutics to Host Virtual R&D Day on March 11, 2022
-
Cara Therapeutics to Host Virtual R&D Day on March 11, 2022
-
Cara Therapeutics (CARA) Reports Positive Phase 3 Results in Japan for Difelikefalin Injection
-
Cara Therapeutics Announces Difelikefalin (KORSUVA™) Injection Achieves Positive Topline Results in Phase 3 Clinical Study in Japan for the Treatment of Pruritus in Hemodialysis Patients
-
Cara Therapeutics Announces Difelikefalin (KORSUVA™) Injection Achieves Positive Topline Results in Phase 3 Clinical Study in Japan for the Treatment of Pruritus in Hemodialysis Patients
-
Cara Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
-
Cara Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
-
Cara Therapeutics (CARA) Announces CMS Grants TDAPA to KORSUVA Injection
-
Cara Therapeutics Announces CMS Grants TDAPA to KORSUVA™ (difelikefalin) Injection
-
Cara Therapeutics Announces CMS Grants TDAPA to KORSUVA™ (difelikefalin) Injection
-
CytomX Therapeutics Appoints Dr. Mani Mohindru to Board of Directors
-
SAB Biotherapeutics Announces New Appointments to its Board of Directors
-
Streetinsider.com's Hot Lunchtime Reads 10/29: (TWTR) (BBRY) (ORB) (TGT)
-
Cara Therapeutics, Inc. [CARA] to Ring The NASDAQ Stock Market Opening Bell

